Skip to main content

Journal Club - September 2, 2021

EMPEROR-Preserved Trial

Dr. Charmaine Lam will presented the EMPEROR-Preserved Trial, which is a double-blind, randomized control trial comparing the use of empagliflozin (10mg) to placebo among patients with class II–IV heart failure and an ejection fraction of more than 40% looking at the primary composite outcome of cardiovascular death or hospitalization for heart failure.

Click link to view Zoom Recording

CCI is an inclusive centre with multidisciplinary membership for all cardiovascular investigators in BC